Fortress Biotech, Inc. (FBIO)
2.52
-0.05
(-1.95%)
USD |
NASDAQ |
Sep 11, 16:00
2.51
-0.01
(-0.40%)
After-Hours: 07:08
Fortress Biotech Enterprise Value : -17.37M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | -17.37M |
| September 10, 2026 | -15.70M |
| September 09, 2026 | -13.70M |
| September 08, 2026 | -11.04M |
| September 04, 2026 | -10.71M |
| September 03, 2026 | -11.04M |
| September 02, 2026 | -10.37M |
| September 01, 2026 | -12.04M |
| August 31, 2026 | -10.21M |
| August 28, 2026 | -9.040M |
| August 27, 2026 | -8.040M |
| August 26, 2026 | -7.707M |
| August 25, 2026 | -7.041M |
| August 24, 2026 | -3.710M |
| August 21, 2026 | -5.708M |
| August 20, 2026 | -9.040M |
| August 19, 2026 | -6.375M |
| August 18, 2026 | -4.376M |
| August 17, 2026 | -7.374M |
| August 14, 2026 | -3.710M |
| August 13, 2026 | -2.044M |
| August 12, 2026 | -9.706M |
| August 11, 2026 | -14.37M |
| August 10, 2026 | -9.706M |
| August 07, 2026 | -12.37M |
| Date | Value |
|---|---|
| August 06, 2026 | -9.040M |
| August 05, 2026 | -8.373M |
| August 04, 2026 | -10.71M |
| August 03, 2026 | -9.373M |
| July 31, 2026 | 2.952M |
| July 30, 2026 | 8.282M |
| July 29, 2026 | 10.28M |
| July 28, 2026 | 11.61M |
| July 27, 2026 | 7.616M |
| July 24, 2026 | 9.948M |
| July 23, 2026 | 12.95M |
| July 22, 2026 | 16.94M |
| July 21, 2026 | 16.28M |
| July 20, 2026 | 9.615M |
| July 17, 2026 | 10.61M |
| July 16, 2026 | 12.61M |
| July 15, 2026 | 22.27M |
| July 14, 2026 | 22.94M |
| July 13, 2026 | 8.615M |
| July 10, 2026 | 8.615M |
| July 09, 2026 | 8.282M |
| July 08, 2026 | -1.378M |
| July 07, 2026 | -1.711M |
| July 06, 2026 | -3.044M |
| July 02, 2026 | -0.0456M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Inovio Pharmaceuticals, Inc. | 74.26M |
| Kura Oncology, Inc. | 518.62M |
| Spero Therapeutics, Inc. | 16.98M |
| ACADIA Pharmaceuticals, Inc. | 3.908B |
| Alnylam Pharmaceuticals, Inc. | 32.94B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.602M |
| Revenue (Quarterly) | 18.72M |
| Total Expenses (Quarterly) | 19.19M |
| EPS Diluted (Quarterly) | -0.0779 |
| Gross Profit Margin (Quarterly) | 61.50% |
| Profit Margin (Quarterly) | 3.22% |
| Earnings Yield | 105.4% |
| Normalized Earnings Yield | 97.17 |